Compass Pathways表示，其Comp360裸盖菇素可以是治疗难治性抑郁症的单一疗法，也可以与SSRI一起使用

09:43 AM EST, 12/13/2021 (MT Newswires) -- Compass Pathways (CMPS) said Monday data from an exploratory study of its Comp360 psilocybin therapy for treatment-resistant depression shows it could be a montherapy as well as an adjunctive treatment to a selective seratonin reuptake inhibitor antidepressant.

In the study, 19 patients taking concomitant SSRI therapy with a single 25-milligram dose of Comp360 saw comparable treatment outcomes to patients in a phase IIb trial who were withdrawn from SSRI prior to receiving Comp360, the company said.

Comp360 using a 25-milligram dose also showed overall signals of improvement in most other measures including anxiety, clinician and self-rated depressive symptoms, and positive and negative affect, with all patients tolerating the therapy well.

Compass Pathways said it is targeting a meeting with the US Food and Drug Administration in early 2022 to finalize a phase III program that it expects to start in Q3 2022.